Ketamine One Announces 2021 AGSM Results
VANCOUVER, British Columbia, Dec. 20, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce the results of voting at its annual general and special meeting of shareholders which was held on December 17, 2021 in Vancouver, British Columbia (the “Meeting”). There were 11 shareholders represented in person or by proxy at the Meeting holding 18,857,552 common shares, representing 15.69% of the Company’s total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting is set out below:
Number of Directors
As previously announced on December 15, 2021, Mr. Peter Nguyen resigned from the Company’s board of directors and will no longer stand for re-election. Therefore, the resolution to set the number of directors of the Company at four (4) was approved by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:
| Votes For | Votes Against | ||||
| # | % | # | % | ||
| 18,612,552 | 98.7% | 245,000 | 1.29% | ||
Election of Directors
Each of the nominees for election as director listed in the Company’s management information circular dated November 12, 2021 were elected as directors of the Company for the ensuing year until their successors are elected or appointed. Voting results are set out below:
| Votes For | Votes Withheld | |||||
| # | % | # | % | |||
| James Henning | 18,612,517 | 98.7% | 245,035 | 1.29% | ||
| Natasha Raey | 18,612,552 | 98.7% | 245,000 | 1.29% | ||
| Brendan Purdy | 18,606,942 | 98.7% | 250,610 | 1.33% | ||
| Steven Inglefield | 18,606,942 | 98.7% | 250,610 | 1.33% | ||
Appointment of Auditors
Macias Gini & O’Connell, LLP, Chartered Professional Accountants were reappointed as Auditors of the Company for the ensuing year with their remuneration to be fixed by the Board of Directors. Voting results are set out below:
| Votes For | Votes Withheld | ||||
| # | % | # | % | ||
| 18,857,552 | 100% | 0 | 0% | ||
Approval of Restricted Share Unit Plan
The resolution to authorize and approve the restricted share unit plan of the Company was approved by a majority of votes cast by the disinterested shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:
| Votes For | Votes Against | ||||
| # | % | # | % | ||
| 18,607,027 | 98.7% | 250,525 | 1.33% | ||
Approval of Grant of Restricted Share Units
The resolution to authorize and approve the grant of restricted share units in September 2021 was approved by a majority of votes cast by the disinterested shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:
| Votes For | Votes Against | ||||
| # | % | # | % | ||
| 18,606,992 | 98.7% | 250,560 | 1.33% | ||
ABOUT KETAMINE ONE
KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further consolidate the highly fragmented industry. KGK Science Inc. is the Company’s wholly owned contract research division, which places it at the forefront of premium clinical research based on the subsidiary’s history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.
On behalf of:
KETAMINE ONE
“Adam Deffett“
Adam Deffett, Interim CEO
For further information, please contact:
Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: IR@ketamine.one
Web: www.ketamine.one
Twitter: @KetamineOne
Notice Regarding Forward-Looking Information:
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.
The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.
